{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:33:30Z","timestamp":1794584010303,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K18295"],"award-info":[{"award-number":["JP20K18295"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis characterized by eosinophil-rich granulomatous inflammation and small-to-medium vessel vasculitis associated with asthma, rhinosinusitis, and eosinophilia. EGPA is often difficult to distinguish from severe asthma and eosinophilic chronic rhinosinusitis (ECRS) in cases when there are no findings that suggest vasculitis. Dupilumab, an anti-IL-4R\u03b1 monoclonal antibody, is expected to be effective in eosinophilic airway inflammatory diseases, such as refractory asthma and chronic rhinosinusitis (CRS). Although transient eosinophilia and eosinophilic pneumoniae have been reported in patients with refractory asthma and CRS associated with dupilumab, few studies have examined the development of EGPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a 61-year-old woman treated with dupilumab for refractory ECRS and eosinophilic otitis media (EOM) complicated by severe asthma. Although she had a previous history of eosinophilic pneumoniae and myeloperoxidase (MPO) ANCA positivity, there were no apparent findings of vasculitis before the initiation of dupilumab. After the second administration of dupilumab, several adverse events developed, including worsening of ECRS, EOM and asthma, and neuropathy. A blood test showed an eosoinophilia and re-elevation of MPO-ANCA levels after the administration of dupilumab. Therefore, dupilumab was discontinued owing to the development of EGPA, and prednisolone and azathioprine administration was initiated for a remission induction therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To the best of our knowledge, this is the first case report that suggests that dupilumab may directly trigger the manifestation of vasculitis in patients who were previously MPO-ANCA-positive. Although the precise mechanism of how dupilumab could trigger the development of EGPA requires further elucidation, measuring MPO-ANCA in patients with multiple eosinophilic disorders before the initiation of dupilumab might be helpful when considering the possibility of a latent EGPA. When administering dupilumab to patients with a previous history of MPO-ANCA positivity, clinicians must carefully monitor and collaborate with other specialists in the pertinent fields of study for appropriate usage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-023-02415-6","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:02:18Z","timestamp":1681887738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Isao","family":"Suzaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawa","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitome","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"4","key":"2415_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","volume":"68","author":"S Furuta","year":"2019","unstructured":"Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68(4):430\u20136. https:\/\/doi.org\/10.1016\/j.alit.2019.06.004.","journal-title":"Allergol Int"},{"issue":"5","key":"2415_CR2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1183\/13993003.00097-2016","volume":"48","author":"V Cottin","year":"2016","unstructured":"Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48(5):1429\u201341. https:\/\/doi.org\/10.1183\/13993003.00097-2016.","journal-title":"Eur Respir J"},{"issue":"4","key":"2415_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.alit.2019.07.002","volume":"68","author":"S Fujieda","year":"2019","unstructured":"Fujieda S, Imoto Y, Kato Y, Ninomiya T, Tokunaga T, Tsutsumiuchi T, et al. Eosinophilic chronic rhinosinusitis. Allergol Int. 2019;68(4):403\u201312. https:\/\/doi.org\/10.1016\/j.alit.2019.07.002.","journal-title":"Allergol Int"},{"issue":"8","key":"2415_CR4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/all.12644","volume":"70","author":"T Tokunaga","year":"2015","unstructured":"Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015;70(8):995\u20131003. https:\/\/doi.org\/10.1111\/all.12644.","journal-title":"Allergy"},{"issue":"4","key":"2415_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.anl.2010.11.016","volume":"38","author":"Y Iino","year":"2011","unstructured":"Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx. 2011;38(4):456\u201361.","journal-title":"Auris Nasus Larynx"},{"key":"2415_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.01.002","author":"K Matsunaga","year":"2020","unstructured":"Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K, Dupilumab. Basic aspects and applications to allergic diseases. Allergol Int. 2020. https:\/\/doi.org\/10.1016\/j.alit.2020.01.002.","journal-title":"Allergol Int"},{"issue":"10209","key":"2415_CR7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350. https:\/\/doi.org\/10.1016\/s0140-6736(19)31881-1.","journal-title":"Lancet"},{"issue":"1","key":"2415_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s2213-2600(21)00322-2","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11\u201325. https:\/\/doi.org\/10.1016\/s2213-2600(21)00322-2.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2415_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification Criteria for Eosinophilic granulomatosis with Polyangiitis. Ann Rheum Dis. 2022;81(3):309\u201314. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221794.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2415_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2169\/internalmedicine.7990-21","volume":"61","author":"M Ikeda","year":"2022","unstructured":"Ikeda M, Ohshima N, Kawashima M, Shiina M, Kitani M, Suzukawa M. Severe asthma where Eosinophilic granulomatosis with Polyangiitis Became Apparent after the discontinuation of Dupilumab. Intern Med. 2022;61(5):755\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.7990-21.","journal-title":"Intern Med"},{"issue":"7","key":"2415_CR11","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1016\/j.jaip.2021.02.042","volume":"9","author":"K Eger","year":"2021","unstructured":"Eger K, Pet L, Weersink EJM, Bel EH. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract. 2021;9(7):2913\u20135. https:\/\/doi.org\/10.1016\/j.jaip.2021.02.042.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2415_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223596","author":"M von Deimling","year":"2022","unstructured":"von Deimling M, Koehler TC, Frye BC, Maerker-Hermann E, Venhoff N. Two cases with new onset of ANCA-positive eosinophilic granulomatosis with polyangiitis under treatment with dupilumab: coincidence or causality? Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-223596.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2415_CR13","doi-asserted-by":"publisher","first-page":"e27670","DOI":"10.7759\/cureus.27670","volume":"14","author":"P Persaud","year":"2022","unstructured":"Persaud P, Karmali R, Sankar P, Majid M. Dupilumab-Associated Eosinophilic Granulomatosis with Polyangiitis. Cureus. 2022;14(8):e27670. https:\/\/doi.org\/10.7759\/cureus.27670.","journal-title":"Cureus"},{"issue":"5","key":"2415_CR14","doi-asserted-by":"publisher","first-page":"e25218","DOI":"10.7759\/cureus.25218","volume":"14","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Tsuji T, Shiotsu S, Yuba T, Hiraoka N. Exacerbation of Eosinophilic Granulomatosis with Polyangiitis after administering dupilumab for severe asthma and eosinophilic Rhinosinusitis with nasal polyposis. Cureus. 2022;14(5):e25218. https:\/\/doi.org\/10.7759\/cureus.25218.","journal-title":"Cureus"},{"key":"2415_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.03.005","author":"Y Nishiyama","year":"2022","unstructured":"Nishiyama Y, Koya T, Nagano K, Abe S, Kimura Y, Shima K, et al. Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology? Allergol Int. 2022. https:\/\/doi.org\/10.1016\/j.alit.2022.03.005.","journal-title":"Allergol Int"},{"issue":"1","key":"2415_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000442040","volume":"21","author":"Y Nakamaru","year":"2016","unstructured":"Nakamaru Y, Takagi D, Suzuki M, Homma A, Morita S, Homma A, et al. Otologic and rhinologic manifestations of Eosinophilic granulomatosis with Polyangiitis. Audiol Neurootol. 2016;21(1):45\u201353. https:\/\/doi.org\/10.1159\/000442040.","journal-title":"Audiol Neurootol"},{"key":"2415_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1196\/annals.1361.053","volume":"1051","author":"B Hellmich","year":"2005","unstructured":"Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121\u201331. https:\/\/doi.org\/10.1196\/annals.1361.053.","journal-title":"Ann N Y Acad Sci"},{"issue":"9842","key":"2415_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s0140-6736(12)60988-x","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(12)60988-x.","journal-title":"Lancet"},{"issue":"13","key":"2415_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa1403290.","journal-title":"N Engl J Med"},{"issue":"5","key":"2415_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s2213-2600(17)30125-x","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390\u2013400. https:\/\/doi.org\/10.1016\/s2213-2600(17)30125-x.","journal-title":"Lancet Respir Med"},{"issue":"13","key":"2415_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1403291.","journal-title":"N Engl J Med"},{"issue":"20","key":"2415_CR22","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or Placebo for Eosinophilic granulomatosis with Polyangiitis. N Engl J Med. 2017;376(20):1921\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702079.","journal-title":"N Engl J Med"},{"issue":"10","key":"2415_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353. https:\/\/doi.org\/10.1016\/s2213-2600(21)00097-7.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2415_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/1529-0131(200102)44:2<469::Aid-anr66>3.0.Co;2-0","volume":"44","author":"M Kiene","year":"2001","unstructured":"Kiene M, Csernok E, M\u00fcller A, Metzler C, Trabandt A, Gross WL. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum. 2001;44(2):469\u201373. https:\/\/doi.org\/10.1002\/1529-0131(200102)44:2<469::Aid-anr66>3.0.Co;2-0.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2415_CR25","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1016\/j.jaip.2020.06.052","volume":"8","author":"J Galant-Swafford","year":"2020","unstructured":"Galant-Swafford J, Geng B, Leibel S, Akuthota P, Tucker S, Cernelc-Kohan M, et al. Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab. J Allergy Clin Immunol Pract. 2020;8(10):3643\u20136e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.06.052.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"2415_CR26","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1016\/j.jaip.2021.06.033","volume":"9","author":"A Matucci","year":"2021","unstructured":"Matucci A, Bormioli S, Bercich L, Comin CE, Bezzi M, Vivarelli E, et al. Effect of dupilumab treatment in a severe asthma patient with EGPA. J allergy Clin Immunol Pract. 2021;9(10):3824\u20135. https:\/\/doi.org\/10.1016\/j.jaip.2021.06.033.","journal-title":"J allergy Clin Immunol Pract"},{"issue":"1","key":"2415_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13223-021-00639-x","volume":"18","author":"S Adachi","year":"2022","unstructured":"Adachi S, Oshikata C, Kaneko T, Tsurikisawa N. Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi. Allergy Asthma Clin Immunol. 2022;18(1):18. https:\/\/doi.org\/10.1186\/s13223-021-00639-x.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02415-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:02:32Z","timestamp":1681887752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02415-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2415"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02415-6","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study was approved by Showa University ethical committee (approval number 3351).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of the patient\u2019s clinical details and clinical images was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}